Why Editas Medicine Stock Sank Today
Shares of Editas Medicine (NASDAQ: EDIT) were down 6.8% as of 3:51 p.m. EST on Thursday. The company didn't report any news that would cause its stock to fall. Instead, Editas' decline resulted from the overall stock market sell-off.
Clinical-stage biotech stocks tend to be a lot more volatile than the major benchmark indexes. When the market drops, these stocks often fall even harder.
What should investors do? Sit tight. Market swings come and they go. The important thing to focus on is Editas' prospects for its gene-editing therapies in development.
Source Fool.com